600789 鲁抗医药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入4,624,350-0.91%6,233,0906,146,7215,621,4424,923,784
减:营业总成本4,428,404-2.58%5,966,9795,907,6645,455,3694,793,389
    其中:营业成本3,620,252-0.78%4,739,4694,631,2684,373,9623,746,105
               财务费用37,926-16.17%53,59066,63978,20168,159
               资产减值损失(49,281)-1,500.88%(66,943)(54,682)(41,938)(30,942)
公允价值变动收益(71)-252.63%30(69)52113
投资收益(3,111)-47.39%(7,591)(7,134)(6,582)(3,296)
    其中:对联营企业和合营企业的投资收益(3,211)-45.70%(7,673)(7,169)(6,611)(3,295)
营业利润190,331-48.91%436,190272,133148,774116,019
利润总额186,336-49.95%433,901272,975150,095113,579
减:所得税费用39,717157.75%25,55416,1886,98023,687
净利润146,619-58.92%408,348256,787143,11589,891
减:非控股权益5,423-45.00%13,73210,6155,102793
股东净利润141,196-59.32%394,616246,172138,01389,099

市场价值指针
每股收益 (元) *0.160-58.97%0.4400.2800.1600.100
每股派息 (元) *----0.1320.0900.0550.050
每股净资产 (元) *4.4031.63%4.3604.0313.7853.695
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容